As further prospective studies validate these findings, multi-parametric MRI-based radiomics features are anticipated to offer valuable clinical insights for preoperative assessment and evaluation of NAT efficacy in HER2 overexpressing breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.